

ClinixBoost Summary Report

Clinical Trial Rules Engine

Generated on June 06, 2026 at 09:12 PM | rajiv.dulepet

Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

Session Results

Matches: 14

Needs Data: 11

Excluded: 408

Matched Trials:

[NCT03757182](#) - Digitally-Captured Step Counts for Evaluating Performance Status in Ad
[NCT04896697](#) - A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastob
[NCT05401110](#) - IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuxim
[NCT05533697](#) - Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination Wit
[NCT05941507](#) - A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy o
[NCT06060613](#) - A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy o
[NCT06108050](#) - A Phase 1, First-in-human, Open-label, Multicenter Study of JZP898 as
[NCT06425926](#) - A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerabilit
[NCT06544655](#) - A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Com
... and 5 more

Needs More Data:

[NCT04585750](#) - A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolera
[NCT04886804](#) - Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dos
[NCT05083481](#) - A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pe
[NCT05101070](#) - A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy
[NCT05786924](#) - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monothera
... and 6 more

Generated by ClinixBoost Clinical Trial Rules Engine